Next Generation Therapy:
Journey from clinical to commercial
Caught beneath the surface: The hidden potential of patient data
AI-powered insights from structured and unstructured data speed diagnoses, reveal patient behaviors, and enable more personalized care.
Taming the Complexity of CGT Commercialization
How five strategic levers help companies design an executable CGT commercialization model.
Initial CGT launches faltered. The next wave doesn’t have to.
Explore four key considerations for commercializing the next generation of potentially curative therapies.
How to Make Cell & Gene Therapy Commercialization Work:
Key Learnings from Leaders Who’ve Been There
Cell and gene therapies promise breakthrough outcomes, but many stumble at launch. In this panel, leaders from Novartis, Orca Bio, BioMarin, and Beghou share real-world lessons on what drives CGT success, from cross-functional collaboration to adapting models to meet commercialization challenges.
Additionally, listen to our two-part podcast series featuring Rita (COO, ARM), which focuses on navigating CGT complexities.
The Beghou difference
AI that fits your world and grows with it.
We design AI strategies grounded in your therapeutic context and aligned with real business goals. Combining deep life sciences expertise with data science rigor, we deliver adaptable solutions that drive adoption, create long-term value, and scale with your organization.
Our approach centers on practical, high-impact meta use cases with measurable ROI. We work across commercial, medical, and IT teams to ensure AI becomes an integrated part of your operations. And with compliance, security, and scalability built in from the start, you get technology you can trust and outcomes you can track.
“Cell and gene therapies work, but the challenge of modern medicine is to identify the right unmet need in a disease area, provide equitable access to patients, and scale the manufacturing and distribution in order to transform patient lives.”
